L3VLUP
ProSign in

ALNY · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALNYJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALNY
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterALNYJNJ
Q3 202013 holders, $7.6bn30 holders, $26.2bn
Q4 202013 holders, $6.5bn32 holders, $26.6bn
Q1 202114 holders, $7.2bn31 holders, $25.3bn
Q2 202113 holders, $8.8bn37 holders, $25.6bn
Q3 202114 holders, $9.7bn40 holders, $24.1bn
Q4 202112 holders, $8.8bn33 holders, $25.2bn
Q1 202212 holders, $8.9bn35 holders, $28.2bn
Q2 202213 holders, $8.1bn33 holders, $26.9bn
Q3 202217 holders, $10.8bn36 holders, $25.4bn
Q4 202216 holders, $13.7bn35 holders, $27.6bn
Q1 202319 holders, $11.5bn42 holders, $24.5bn
Q2 202316 holders, $10.6bn38 holders, $25.0bn
Q3 202317 holders, $9.7bn37 holders, $18.9bn
Q4 202315 holders, $10.0bn31 holders, $19.0bn
Q1 202415 holders, $7.3bn32 holders, $19.7bn
Q2 202419 holders, $12.5bn35 holders, $20.4bn
Q3 202418 holders, $15.1bn28 holders, $22.3bn
Q4 202415 holders, $12.8bn37 holders, $20.4bn
Q1 202518 holders, $14.9bn32 holders, $20.5bn
Q2 202522 holders, $18.3bn31 holders, $18.4bn
Q3 202533 holders, $26.6bn32 holders, $23.7bn
Q4 202524 holders, $23.4bn29 holders, $27.8bn
Q1 202622 holders, $17.9bn34 holders, $35.6bn
Q2 202621 holders, $15.9bn33 holders, $39.1bn
ALNY

Alnylam Pharmaceuticals Inc

Holders
22
Reported value
$18.3bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALNY (7)

Baillie Gifford & Co, Balyasny Asset Management LLC, Capital World Investors, Citadel Advisors LLC, Holocene Advisors LP, Schonfeld Strategic Advisors LLC, Walleye Capital LLC

Only JNJ (16)

Acadian Asset Management LLC, AllianceBernstein LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Caxton Associates LLP, D. E. Shaw & Co., Eisler Capital Management Ltd, GAMCO Investors Inc, Man Group PLC, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Verition Fund Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →